Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control. 2006

J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
Department of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA. jmathi@lsuhsc.edu

Two technical hurdles, gene delivery and target specificity, have hindered the development of effective cancer gene therapies. In order to circumvent the problem of tumor specificity, the suicide gene, HSV-1 thymidine kinase (HSV-Tk), was modified with a complex 5' upstream-untranslated region (5'-UTR) that limits efficient translation to cells expressing high levels of the translation initiation factor, eIF4E. Since previous studies have shown that most tumor cells express elevated levels of eIF4E, tumor-specific gene delivery was optimized by incorporation of the 5'-UTR-modified suicide gene (HSV-UTk) into an adenovirus vector (Ad-CMV-UTk). The efficacy of this novel approach of targeting suicide gene expression and limiting cytotoxicity by means of translational restriction was tested in vitro with the use of the human breast cancer cell lines (MCF-7, MDA-MB435, and ZR-75-1). As controls, normal MCF10A, HMEC, and HMSC cell lines that express relatively low levels of eIF4E were used. Real-time reverse-transcription polymerase chain reaction (RT-PCR) was used to quantify HSV-Tk mRNA for cells infected with Ad-CMV-UTk as well as with Ad-CMV-Tk (a control adenovirus in which HSV-Tk is not regulated at the level of translation). Translation of HSV-Tk in the Ad-infected cells was measured by Western blot analysis. In addition, cytotoxicity was determined following treatment with the pro-drug ganciclovir (GCV) using an MTT viability assay. Finally, microPET imaging was used to assess cancer cell-specific expression of HSV-Tk and expression in normal tissues in vivo after intraperitoneal injection of Ad-CMV-Tk or Ad-CMV-UTk. These data collectively showed enhanced cancer cell-specific gene expression and reduced normal tissue gene expression for the Ad-HSV-UTk compared to the Ad-CMV-Tk, leading to increased cancer cell-enhanced GCV cytotoxicity. These results indicate that translational targeting of suicide gene expression in tumor cells in vitro and in vivo is effective and may provide a platform for enhanced cancer gene therapy specificity.

UI MeSH Term Description Entries
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005814 Genes, Viral The functional hereditary units of VIRUSES. Viral Genes,Gene, Viral,Viral Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000260 Adenoviruses, Human Species of the genus MASTADENOVIRUS, causing a wide range of diseases in humans. Infections are mostly asymptomatic, but can be associated with diseases of the respiratory, ocular, and gastrointestinal systems. Serotypes (named with Arabic numbers) have been grouped into species designated Human adenovirus A-G. APC Viruses,APC Virus,Adenovirus, Human,Human Adenovirus,Human Adenoviruses
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D013937 Thymidine Kinase An enzyme that catalyzes the conversion of ATP and thymidine to ADP and thymidine 5'-phosphate. Deoxyuridine can also act as an acceptor and dGTP as a donor. (From Enzyme Nomenclature, 1992) EC 2.7.1.21. Deoxythymidine Kinase,Deoxypyrimidine Kinase,Kinase, Deoxypyrimidine,Kinase, Deoxythymidine,Kinase, Thymidine
D014176 Protein Biosynthesis The biosynthesis of PEPTIDES and PROTEINS on RIBOSOMES, directed by MESSENGER RNA, via TRANSFER RNA that is charged with standard proteinogenic AMINO ACIDS. Genetic Translation,Peptide Biosynthesis, Ribosomal,Protein Translation,Translation, Genetic,Protein Biosynthesis, Ribosomal,Protein Synthesis, Ribosomal,Ribosomal Peptide Biosynthesis,mRNA Translation,Biosynthesis, Protein,Biosynthesis, Ribosomal Peptide,Biosynthesis, Ribosomal Protein,Genetic Translations,Ribosomal Protein Biosynthesis,Ribosomal Protein Synthesis,Synthesis, Ribosomal Protein,Translation, Protein,Translation, mRNA,mRNA Translations
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic

Related Publications

J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
February 1999, Human gene therapy,
J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
May 2002, Human gene therapy,
J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
March 2008, Ultrasound in medicine & biology,
J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
January 1999, Gynecologic oncology,
J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
March 2010, International journal of molecular medicine,
J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
February 2004, World journal of gastroenterology,
J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
April 2015, Cancer gene therapy,
J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
June 1996, Human gene therapy,
J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
January 2000, Anticancer research,
J Michael Mathis, and B Jill Williams, and Don A Sibley, and Jennifer L Carroll, and Jie Li, and Yoshinobu Odaka, and Shayne Barlow, and Cherie-Ann O Nathan, and Benjamin D L Li, and Arrigo DeBenedetti
January 1976, Bulletin du cancer,
Copied contents to your clipboard!